New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-13 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES1

STORY SIZESTANDALONE

FIRST SEEN2026-10-13 12:00 UTC

LAST UPDATE2026-10-13 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Takeda's zasocitinib PsA trial expands its immunology pipeline bet.

Takeda advances zasocitinib in psoriatic arthritis

CATALYST TO WATCH

Phase 3 data readout

MAIN RISK

PsA market is highly competitive

FULL DISPATCH

Sponsor: Takeda; Status: Not Yet Recruiting; Conditions: Psoriatic Arthritis; Interventions: Placebo, Zasocitinib; Enrollment: 644 (estimated); First posted: 2026-10-13; NCT: NCT07871721

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-13 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC

→CORRELATIONshares Healthcare
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC

→CORRELATIONshares Healthcare
New Phase 3 trial: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight — Amgen2026-10-13 12:00 UTC

←INFERENCEfilings generate company commentary
JPM filed 8-K on 2026-10-132026-10-13 00:00 UTC

←INFERENCEfilings generate company commentary
UNH filed 8-K on 2026-10-132026-10-13 00:00 UTC

←INFERENCEfilings generate company commentary
GS filed 8-K on 2026-10-132026-10-13 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.